Bo Hansen - Karolinska Development Insider

Karolinska Development AB -- Sweden Stock  

SEK 5.40  0.20  3.57%

Chairman of the Board

Dr. Bo Jesper Hansen M.D. Ph.D. was Independent Chairman of the Board of Karolinska Development AB since October 1 2013. He is Member of the Asian Committee and Chairman of Remuneration and Audit Committees. He was Director of the Company since May 14 2013. He is also Chairman of Swedish Orphan Biovitrum AB and Board member of GenSpera Inc. Newron SA Ablynx NV Orphazyme AS and CMC Kontrast AB. His previous appointments include various positions in Swedish Orphan International AB since 1993 including CEO . He was Medical advisor for Synthelabo Pfizer Pharmacia and Yamanouchi. He is Founder of Scandinavian Medical Research.
Age: 57  Chairman Since 2013  Ph.D    
46 8 52 48 60 70  http://www.karolinskadevelopment.com

Management Efficiency

The company has return on total asset (ROA) of (3.86) % which means that it has lost $3.86 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of 120.96 % meaning that it generated $120.96 on every $100 dollars invested by stockholders.
The company has accumulated 379.18 M in total debt with debt to equity ratio (D/E) of 141.9 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Karolinska Development AB has Current Ratio of 13.84 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.

Similar Executives

Found 7 records

CHAIRMAN Since

Rune NordlanderSprint Bioscience AB
N/A
Bjorn NilssonBioInvent International AB
2011
Saeid EsmaeilzadehXbrane Biopharma AB
2008
Ulf LindbergKaressa Pharma Holding AB
2017
Gregory BatchellerXintela AB
2017
Ulf TossmanKaressa Pharma Holding AB
2016
Martin NilssonKaressa Pharma Holding AB
2015

Entity Summary

Karolinska Development AB is a venture capital firm specializing in investments in growth capital, seed stage, and early stage companies. Karolinska Development AB was founded in 2003 and is headquartered in Stockholm, Sweden. Karolinska Development operates under Pharmaceuticals And Biosciences classification in Sweden and traded on Stockholm Stock Exchange exchange.Karolinska Development AB (KDEV) is traded on Stockholm Stock Exchange in Sweden. It is located in Tomtebodav?gen 23 A and employs 13 people.

Did you try this?

Run Analyst Recommendations Now
   

Analyst Recommendations

Analyst recommendations and target price estimates broken down by several categories
Hide  View All  NextLaunch Analyst Recommendations
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Karolinska Development AB to your portfolio

Top Management

Karolinska Development AB Leadership Team
Hans Wigzell, Chairman, Ph.D
Elisabet Gimbringer, Executive
Carl Sundberg, Director
Magnus Persson, Director, Ph.D
Jim Heusden, CEO, Ph.D
Maria Ferm, Executive
HansOlov Olsson, Director, Ph.D
Theresa Tse, Director
Viktor Drvota, Executive, Ph.D
Eva Montgomerie, Executive
Michael Owens, Executive
Yan Cheng, President
Ulf Richenberg, Executive
Niclas Adler, Director
Tse Ping, Director, Ph.D
Christian Tange, CFO, MBA
Daniel Bolanowski, Executive
Terje Kalland, Executive, Ph.D
Vladimir Artamonov, Director, MBA
Felicia Rittemar, Executive
AnnSofie Sternas, President
Anders Harfstrand, Director, Ph.D
Bo Hansen, Chairman, Ph.D
Fredrik Jarrsten, CFO
Khalid Islam, Director, Ph.D
Gunilla Ekstrom, President, Ph.D
Henrijette Richter, Director

Stock Performance

Karolinska Development Performance Indicators